3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      miR-486-5p inhibits cell growth of papillary thyroid carcinoma by targeting fibrillin-1.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Previous studies have demonstrated that miR-486-5p functions as a tumor suppressor or oncogene in various types of cancer. In the present study, we showed that miR-486-5p was significantly down-regulated in papillary thyroid carcinoma (PTC) tissues and cell lines, whereas miR-486-5p down-regulation inhibited PTC cell proliferation and increased apoptosis. Conversely, under-expression of miR-486-5p enhanced PTC cell proliferation and decreased apoptosis. Fibrillin-1 (FBN1) was shown to be a direct target of miR-486-5p and inversely regulated by miR-486-5p. FBN1 silencing led to decreased PTC cell proliferation and enhanced apoptosis in vitro, similar to that mediated by miR-486-5p. Furthermore, miR-486-5p over-expression or FBN1 knock-down inhibited, while up-regulation of FBN1 boosted xenograft tumor formation in vivo. Our data suggest that miR-486-5p induces PTC cell growth inhibition and apoptosis by targeting and suppressing FBN1. Thus, miR-486-5p/FBN1 might provide a promising therapeutic target for PTC treatment.

          Related collections

          Author and article information

          Journal
          Biomed. Pharmacother.
          Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
          Elsevier BV
          1950-6007
          0753-3322
          May 2016
          : 80
          Affiliations
          [1 ] Medical Care Department for Personnel, Urumchi General Hospital of Lanzhou Military Region, Urumchi, Xinjiang 830000, China.
          [2 ] Department of Endocrinology, Urumchi General Hospital of Lanzhou Military Region, Urumchi, Xinjiang 830000, China.
          [3 ] Department of Pharmacy, Urumchi General Hospital of Lanzhou Military Region, Urumchi, Xinjiang 830000, China.
          [4 ] Department of Endocrinology, Urumchi Chinese Medicine Hospital, Urumchi, Xinjiang 830000, China.
          [5 ] Department of Endocrinology, Shanghai Punan Hospital, Shanghai 200125, China.
          [6 ] Department of Endocrinology, The People's Hospital in Altay Region, Altay, Xinjiang 836500, China.
          [7 ] Department of Endocrinology, Urumchi General Hospital of Lanzhou Military Region, Urumchi, Xinjiang 830000, China. Electronic address: jianqing0991@163.com.
          Article
          S0753-3322(15)30526-6
          10.1016/j.biopha.2016.03.020
          27133060

          Comments

          Comment on this article